PHARMACEUTICAL 2014

Alnylam Pharmaceuticals INC
Rank 93 of 234



PHARMACEUTICAL 2014

Alnylam Pharmaceuticals INC
Rank 93 of 234

The relative strengths and weaknesses of Alnylam Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alnylam Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 57% points.The greatest weakness of Alnylam Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 286%, being 43% points above the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	254,028
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	53,864
Liabilities, Non-Current	0
Other Assets	150,054
Other Compr. Net Income	4,055
Other Expenses	-2,695
Other Liabilities	96,319
Other Net Income	48,189
Other Revenues	0
Property and Equipment	16,448
Research and Development	112,957
Selling, General and Administrative Expense	27,152

Output Variable	Value in 1000 USD
Assets	420,530
Liabilities	150,183
Expenses	137,414
Revenues	0
Stockholders Equity	270,347
Net Income	-89,225
Comprehensive Net Income	-87,198
BaseVar	380,186
ECR before LimitedLiability	176%
Economic Capital Ratio	286%